Pasithea Therapeutics
KTTA
7 hedge funds and large institutions have $152K invested in Pasithea Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 2.89% → 2.88% (-0.01%)
31% less capital invested
Capital invested by funds: $218K → $152K (-$66.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.02K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$320 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$39 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.72K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$44 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
ADAR1 Capital Management
Austin,
Texas
| $140K | – | – | – |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $9.14K | +$3.02K | +462 | +34% |
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
4
JP Morgan Chase
New York
| $785 | – | – | – |
|
|
5
Fidelity Investments
Boston,
Massachusetts
| $256 | +$320 | +49 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $192 | -$3.72K | -570 | -94% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $30 | +$39 | +6 | New |
|
|
8
Wells Fargo
San Francisco,
California
| – | -$44 | -6 | Closed |
|
KTTA Hedge Fund Activity: Q2 2024 in Review
7 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q2 2024, worth a combined $152K — down 31% from $218K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KTTA positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $3.02K. The largest seller was UBS Group, cutting an estimated $3.72K.
- 7 institutional investors held Pasithea Therapeutics (KTTA) as of Q2 2024, up from 6 in Q1 2024.
- Funds reported $152K of Pasithea Therapeutics stock for Q2 2024, down 31% quarter-over-quarter.
- 2 funds opened new Pasithea Therapeutics positions in Q2 2024 and 1 closed out, a net change of +1 holder.
- The largest Pasithea Therapeutics buyer in Q2 2024 was Tower Research Capital (TRC), an estimated $3.02K added.
- The largest Pasithea Therapeutics seller in Q2 2024 was UBS Group, an estimated $3.72K sold.
Based on aggregated 13F filings for Q2 2024.